share_log

Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 5.8%

Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 5.8%

串联糖尿病护理(纳斯达克：TNDM)降价5.8
Financial News Live ·  2022/09/19 14:32

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) fell 5.8% during trading on Monday . The stock traded as low as $53.50 and last traded at $53.96. 2,575 shares were traded during trading, a decline of 100% from the average session volume of 850,181 shares. The stock had previously closed at $57.26.

Tandem糖尿病护理公司(纳斯达克代码：TNDM-GET评级)的股价周一在交易中下跌5.8%。该股一度跌至53.50美元，最后报53.96美元。当日成交量为2,575股，较850,181股的平均日成交量下降100%。该股此前收盘价为57.26美元。

Analyst Upgrades and Downgrades

分析师升级和下调评级

TNDM has been the topic of several research analyst reports. StockNews.com lowered shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research note on Friday, September 9th. Robert W. Baird reduced their target price on Tandem Diabetes Care to $76.00 in a research note on Tuesday, August 9th. TheStreet lowered Tandem Diabetes Care from a "c-" rating to a "d+" rating in a research report on Monday, June 13th. Cowen cut their price target on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Finally, Raymond James decreased their price objective on Tandem Diabetes Care from $125.00 to $90.00 and set an "outperform" rating for the company in a report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Tandem Diabetes Care has a consensus rating of "Hold" and an average price target of $103.36.

技术需求管理一直是几份研究分析师报告的主题。在9月9日星期五的一份研究报告中，股票新闻网站将Tandem糖尿病护理公司的股票评级从“持有”下调为“卖出”。罗伯特·W·贝尔德在8月9日星期二的一份研究报告中将Tandem糖尿病护理的目标价格下调至76.00美元。华尔街在6月13日星期一的一份研究报告中将Tandem糖尿病护理的评级从“c-”下调至“d+”。Cowen在8月4日星期四的一份报告中将Tandem糖尿病护理的目标价格从141.00美元下调至107.00美元。最后，雷蒙德·詹姆斯将Tandem糖尿病护理的价格目标从125.00美元下调至90美元，并在8月4日星期四的一份报告中为该公司设定了“跑赢大盘”的评级。两名分析师对该股的评级为卖出，两名分析师给出了持有评级，四名分析师给出了买入评级。根据MarketBeat的数据，Tandem糖尿病护理公司的共识评级为“持有”，平均目标价为103.36美元。

Get
到达
Tandem Diabetes Care
串联糖尿病护理
alerts:
警报：

Tandem Diabetes Care Stock Down 4.6 %

糖尿病护理类股下跌4.6%

The company has a market cap of $3.51 billion, a P/E ratio of -241.09 and a beta of 0.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 6.00 and a quick ratio of 5.36. The stock has a fifty day moving average price of $55.02 and a two-hundred day moving average price of $76.13.

该公司市值为35.1亿美元，市盈率为-241.09，贝塔系数为0.95.该公司的负债权益比为0.63，流动比率为6.00，速动比率为5.36。该股的50日移动均线价格为55.02美元，200日移动均线价格为76.13美元。

Institutional Investors Weigh In On Tandem Diabetes Care

机构投资者对糖尿病护理的看法

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Byrne Asset Management LLC bought a new stake in shares of Tandem Diabetes Care in the 4th quarter worth $34,000. Exane Derivatives bought a new stake in Tandem Diabetes Care in the 1st quarter worth about $33,000. CI Investments Inc. increased its stake in Tandem Diabetes Care by 10,566.7% in the 1st quarter. CI Investments Inc. now owns 320 shares of the medical device company's stock valued at $37,000 after buying an additional 317 shares during the last quarter. Sandy Cove Advisors LLC bought a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $46,000. Finally, KRS Capital Management LLC bought a new position in shares of Tandem Diabetes Care during the 4th quarter worth approximately $60,000. 95.28% of the stock is owned by hedge funds and other institutional investors.
一些机构投资者和对冲基金最近买卖了该股的股票。Byrne Asset Management LLC在第四季度购买了Tandem糖尿病护理公司价值3.4万美元的新股。Exane衍生品在第一季度购买了Tandem糖尿病护理公司的新股份，价值约3.3万美元。CI投资公司在第一季度将其在Tandem糖尿病护理公司的股份增加了10566.7%。CI Investments Inc.现在持有这家医疗设备公司320股股票，价值3.7万美元，此前该公司在上个季度又购买了317股。Sandy Cove Advisors LLC在第一季度购买了Tandem糖尿病护理公司的新股票，价值约4.6万美元。最后，KRS资本管理公司在第四季度购买了Tandem糖尿病护理公司的新股票，价值约6万美元。95.28%的股票由对冲基金和其他机构投资者持有。

About Tandem Diabetes Care

关于糖尿病患者的护理

(Get Rating)

(获取评级)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Tandem糖尿病护理公司是一家医疗设备公司，为美国和国际上的胰岛素依赖型糖尿病患者设计、开发和销售各种产品。该公司的旗舰产品是T：SILM X2胰岛素输送系统，这是一个由T：SILM X2泵、300个单位的一次性胰岛素盒和输液器组成的泵平台。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
  • Still Lovin' It: Investors Keep Visiting McDonald's
  • Did FedEx Just Deliver A Buying Opportunity?
  • Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
  • Upwork Shares Stumble into Bargain Territory
  • Kroger's is Your One-Stop Consumer Staples Stock
  • 免费获取StockNews.com关于串联糖尿病护理(TNDM)的研究报告
  • 仍然爱着它：投资者继续光顾麦当劳
  • 联邦快递刚刚提供了一个买入机会吗？
  • 自动区重新进入拉力赛模式，新高在望
  • Upwork股价跌入便宜货领域
  • 克罗格百货是你的一站式消费者史泰博股票

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

接受每日串联糖尿病护理的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tandem糖尿病护理和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发